Logo of biochemjBJ Latest papers and much more!
Biochem J. 2007 Jan 15; 401(Pt 2): 399–410.
Published online 2006 Dec 21. Prepublished online 2006 Sep 28. doi:  10.1042/BJ20060973
PMCID: PMC1820797

Two metallocarboxypeptidases from the protozoan Trypanosoma cruzi belong to the M32 family, found so far only in prokaryotes


MCPs (metallocarboxypeptidases) of the M32 family of peptidases have been identified in a number of prokaryotic organisms, and only a few of them have been characterized biochemically. Members of this family are absent from eukaryotic genomes, with the remarkable exception of those of trypanosomatids. The genome of the CL Brener clone of Trypanosoma cruzi, the causative agent of Chagas' disease, encodes two such MCPs, with 64% identity between them: TcMCP-1 and TcMCP-2. Both genes, which are present in a single copy per haploid genome, were expressed in Escherichia coli as catalytically active polyHis-tagged recombinant enzymes. Despite their identity, the purified TcMCPs displayed marked biochemical differences. TcMCP-1 acted optimally at pH 6.2 on FA {N-(3-[2-furyl]acryloyl)}-Ala-Lys with a Km of 166 μM. Activity against benzyloxycarbonyl-Ala-Xaa substrates revealed a P1′ preference for basic C-terminal residues. In contrast, TcMCP-2 preferred aromatic and aliphatic residues at this position. The Km value for FA-Phe-Phe at pH 7.6 was 24 μM. Therefore the specificities of both MCPs are complementary. Western blot analysis revealed a different pattern of expression for both enzymes: whereas TcMCP-1 is present in all life cycle stages of T. cruzi, TcMCP-2 is mainly expressed in the stages that occur in the invertebrate host. Indirect immunofluorescence experiments suggest that both proteins are localized in the parasite cytosol. Members of this family have been identified in other trypanosomatids, which so far are the only group of eukaryotes encoding M32 MCPs. This fact makes these enzymes an attractive potential target for drug development against these organisms.

Keywords: Chagas' disease, metallocarboxypeptidase, M32 family of peptidases, Trypanosoma cruzi
Abbreviations: ACE, angiotensin-converting enzyme; CPB, carboxypeptidase B; DAPI, 4′,6-diamidino-2-phenylindole; E-64, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane; FA, N-(3-[2-furyl]acryloyl); GST, glutathione S-transferase; IPTG, isopropyl β-D-thiogalactoside; MCP, metallocarboxy-peptidase; NTA, nitrilotriacetate; ORF, open reading frame; PfuCP, Pyrococcus furiosus carboxypeptidase; TaqCP, Thermus aquaticus carboxypeptidase; TBS, Tris-buffered saline; TcCBP, Trypanosome cruzi serine carboxypeptidase; TcMCP, metallocarboxypeptidase from Trypanosoma cruzi; TOP, thimet oligopeptidase; ZAX, benzyloxycarbonyl-Ala-Xaa


Trypanosoma cruzi, a flagellated protozoan parasite, is the causative agent of the American trypanosomiasis, Chagas' disease. The parasite has a complex life cycle, including two replicative forms: the epimastigote, present in the gut of the insect vector, and the amastigote, an intracellular form in the infected mammal. The two infective non-replicative forms are the metacyclic trypomastigote in the insect vector, and the bloodstream trypomastigote released from infected cells into the blood of the mammal. The infection is endemic in Central and South America where its prevalence is estimated at 16–18 million cases, with 120 million people at risk. No vaccines have been developed so far, and the low effectiveness of the chemotherapeutic agents available makes treatment of Chagas' disease very difficult [1]. There is therefore a pressing need for the identification of novel drug targets and virulence factors to improve the prevention and treatment of this disease. In this context, the study of peptidases in protozoan parasites in general, and in trypanosomatids in particular, has acquired considerable importance over the last decade, since some of them have been proposed to play central roles in diverse processes such as cell invasion, differentiation, cell cycle progression, catabolism of host proteins and evasion of the host immune response [2]. The possibility of developing selective inhibitors of key proteases of pathogenic parasites has been explored vigorously in recent years as a novel chemotherapeutic strategy.

T. cruzi has been shown to contain several proteolytic activities [3]. Among them, the best characterized are endopeptidases, such as the cysteine proteinase, cruzipain, which is the major proteolytic activity in the parasite. Other endopeptidases described more recently include a 30 kDa cathepsin B-like cysteine proteinase [4], two serine proteinases belonging to the prolyl oligopeptidase family [5,6], a GPI (glycosylphosphatidylinositol)-anchored membrane metalloproteinase of the leishmanolysin family [7] and the proteasome [8,9]. The study of exopeptidases in T. cruzi, on the other hand, has received little attention. Except for the detection of some activities (a dipeptidyl aminopeptidase and one or more aminopeptidases) in cell-free extracts [10], and the characterization of a lysosomal serine carboxypeptidase (TcCBP) [11], very little is known about these enzymes.

Carboxypeptidases are peptidases that cleave the C-terminal amino acid residue from peptides and proteins. On the basis of their catalytic mechanism, they are divided into two major classes, namely metallopeptidases and serine peptidases [12]. MCPs (metallocarboxypeptidases) are ubiquitous in Nature and typically have a single zinc ion bound to the active site [13]. Previous studies on Thermus aquaticus, an extremely thermophilic bacterium, led to the identification of a new zinc-dependent MCP [14]. The biochemical characterization of Thermus aquaticus carboxypeptidase (TaqCP) demonstrated that this enzyme was distinct from any other carboxypeptidase in both size and sequence [15]. TaqCP contained a HEXXH signature which is a common conserved sequence found so far in the active site of neutral metalloendopeptidases [15], but not described previously in a carboxypeptidase. These findings demonstrated that TaqCP was a novel type of MCP and the first member of a new and independent family (M32) named as the carboxypeptidase Taq family [16]. Another member of the M32 family that has been characterized is the archaeal Pyrococcus furiosus carboxypeptidase (PfuCP). As with TaqCP, PfuCP is a thermostable enzyme with a broad specificity towards a wide range of C-terminal substrates that include basic, aromatic, neutral and polar amino acids [17]. Important insights into the structural features of this family came from the structure of PfuCP to 2.2 Å (1 Å=0.1 nm) resolution, which revealed that this enzyme has a similar fold to neurolysin, a zinc-dependent endopeptidase that cleaves neurotensin [18].

Sequence alignments have identified M32 family members in species from a very limited phylogenetic range that includes bacteria, archaea and trypanosomatids (including T. cruzi, Trypanosoma brucei, Trypanosoma vivax and Leishmania major), but no metazoa, suggesting that the genes have been acquired by horizontal gene transfer or retained for some special function that is no longer essential for higher organisms.

In the present paper, we report the cloning, sequencing, expression and biochemical characterization of two MCPs from the T. cruzi CL Brener clone belonging to the M32 family (TcMCPs). These are the first members of this family to be characterized in a eukaryotic organism. Our results add to our knowledge of the peptidases present in the parasite, and may offer a new target for the development of a rational chemotherapy against Chagas' disease and other diseases caused by trypanosomatids.



Peptide substrates were purchased from Sigma–Aldrich and Bachem Bioscience. All other reagents were purchased from Sigma unless otherwise stated.

Parasite cultures

The different developmental forms of the parasite (epimastigote, metacyclic trypomastigote, cell-derived trypomastigote and amastigote) of the T. cruzi CL Brener cloned stock [19] were obtained as described previously [20].

DNA purification

DNA was obtained from epimastigotes of T. cruzi by using the Proteinase K/phenol/chloroform method [21].

Southern blot analysis

Genomic DNA (4 μg/reaction) was digested using restriction enzymes according to the manufacturer's instructions (New England Biolabs). DNA fragments were run on a 0.8% agarose gel, transferred on to a nylon membrane (Hybond™-N+; Amersham Biosciences) [22] and UV cross-linked. PCR-amplified fragments of the complete TcMCP-1 or TcMCP-2 ORFs (open reading frames) were labelled with [γ-32P]dCTP following standard procedures [21]. Filters were hybridized with the different probes for 12 h at 62 °C in 0.5 M sodium phosphate buffer, pH 7.4, 1 mM EDTA, 1% BSA and 7% SDS. The membranes were thoroughly washed at 62 °C with 20 mM sodium phosphate buffer, pH 7.4, and 0.1% SDS, and subjected to autoradiography.

Molecular cloning of MCP genes from T. cruzi CL Brener clone

In order to clone both MCP genes from T. cruzi CL Brener clone, four synthetic oligonucleotide primers were designed: TcMCP-1 ATG (5′-GGATCCATGAAGCCGTATAAAGAGCTG-3′); TcMCP-1 STOP (5′-GAATTCTAATCCCCTATCGTCGCGAT-3′); TcMCP-2 ATG (5′-GGATCCATGGAGGCATACAAGAAGCTTG-3′); and TcMCP-2 STOP (5′-GAATTCTTAACCCAAGTTGTCACGATAACG-3′). PCR amplification was carried out using genomic DNA. PCR conditions were as follows: initial denaturation (5 min at 94 °C), denaturation (1 min at 94 °C), annealing (45 s at 62 °C) and elongation (90 s at 72 °C); followed by a final extension step (10 min at 72 °C). The PCR products were isolated from a 1% agarose gel, purified using the Qiaex II protocol (Qiagen) and cloned into pGEM-T Easy vector (Promega). Sequencing of the products was performed using an ABI 377 DNA sequencer (PerkinElmer).

Expression and purification of polyHis-tagged recombinant TcMCPs

TcMCP-1 and TcMCP-2 genes were excised as BamHI/EcoRI fragments from the respective pGEM-T Easy plasmids, gel-purified and subcloned into the BamHI and EcoRI sites of the pTrcHis A expression vector. The resulting constructs presented a polyHis tag at the N-terminus and an enterokinase cleavage site.

pTrcHis A-TcMCP constructs were transformed into Escherichia coli XL1 Blue cells. N-terminally poly-His-tagged fusion proteins were expressed by induction of exponential phase cultures (200 ml; D600=0.6) with 1 mM IPTG (isopropyl β-D-thiogalactoside) for 7 h at 18 °C with vigorous (250 rev./min) shaking. Bacteria were harvested by centrifugation at 5000 g for 30 min at 4 °C, resuspended in 20 ml of 50 mM Tris/HCl, pH 7.6, 150 mM NaCl, 0.1% Triton X-100, 1 mM PMSF and 1 mg/ml lysozyme, and centrifuged at 12000 g for 30 min at 4 °C to obtain the bacterial crude extract.

The recombinant enzymes were purified in one step using Ni- or Co-NTA (nitrilotriacetate) resin (ProBond) pre-equilibrated in 50 mM Tris/HCl buffer, pH 7.6, containing 150 mM NaCl and 20 mM imidazole. The bacterial crude extract was percolated twice through the column which was washed with 50 ml of the equilibration buffer. TcMCPs were eluted with 50 mM Tris/HCl buffer, pH 7.6, 150 mM NaCl and 300 mM imidazole. Samples were desalted using a PD-10 column (Amersham Biosciences) according to the manufacturer's specifications. Sample purity was evaluated on a Coomassie Blue-stained SDS/10% polyacrylamide gel.

For an alternative purification procedure of TcMCP-1, the bacterial crude extract was prepared in the absence of NaCl and applied to a Q-Sepharose column (Sigma) equilibrated in 50 mM Tris/HCl buffer, pH 7.6. The column was washed with 50 ml of the same buffer containing 100 mM NaCl. Recombinant TcMCP-1 was eluted with 50 mM Tris/HCl buffer, pH 7.6, and 200 mM NaCl. The eluate was concentrated using Centriprep YM-30 (Amicon) and applied to a Superdex 200 column (Amersham Biosciences) equilibrated with 50 mM Tris/HCl buffer, pH 7.6, and 250 mM NaCl. The active fractions were pooled, diluted 1/5 with 50 mM Tris/HCl buffer, pH 7.6, and loaded on a MonoQ HR 10/10 anion-exchange column equilibrated with the same buffer. Proteins were eluted with a 0–0.2 M linear NaCl gradient in 8 column vol. Fractions (0.5 ml) were collected at a rate of 1 ml·min−1.

Expression and purification of TcMCPs fused to GST (glutathione S-transferase)

TcMCP-1 and TcMCP-2 genes were also cloned into the BamHI and EcoRI sites of the pGex 2T expression vector (Amersham Biosciences) as described above. Both TcMCP constructs were transformed into E. coli BL21 Codon Plus (DE3) cells. GST-fusion proteins were expressed by induction of exponential phase cultures (200 ml; D600=0.6) with 1 mM IPTG for 12 h at 18 °C with vigorous (250 rev./min) shaking. Bacterial crude extracts were obtained as mentioned above.

Recombinant fusion proteins were purified using a glutathione–agarose resin (Sigma) equilibrated with 50 mM Tris/HCl, pH 7.6, and 150 mM NaCl. The column was washed with 5 column vol. of the equilibration buffer. Samples were eluted with 50 mM Tris/HCl, pH 7.6, and 150 mM NaCl containing 10 mM reduced glutathione.

Gel-filtration experiments

Gel filtration was conducted using a Superose 12HR 10/30 (Pharmacia Biotech) column, eluted with 50 mM Tris/HCl buffer, pH 7.6, containing 0.25 M NaCl. Molecular-mass markers were Vitamin B12 (1.3 kDa), myoglobin (17 kDa), ovalbumin (44 kDa), BSA (66 kDa), and γ-globulin (158 kDa).

Enzyme assays

Routinely, recombinant TcMCP-1 activity was assayed using FA {N-(3-[2-furyl]acryloyl)}-Ala-Lys (200 μM) as substrate in 100 mM Mes, pH 6.2. The hydrolysis of FA-Phe-Phe (100 μM) by recombinant TcMCP-2 was measured in 50 mM Tris/HCl, pH 7.6. Initial steady-state velocity was determined by continuous assay for a range of substrate concentrations at 340 nm with a Beckman DU 650 spectrophotometer. One unit of activity was defined as the amount of enzyme that released 1 μmol of the group being cleaved per min at 25 °C. Kinetic parameters for recombinant TcMCP-1 were determined using FA-Phe-Phe and FA-Ala-Lys in 100 mM Mes, pH 6.2, in the presence or absence of 50 μM CoCl2. Recombinant TcMCP-2 activity was assayed with FA-Phe-Phe in 50 mM Tris/HCl, pH 7.6, also in the presence or absence of 50 μM CoCl2. The substrate preference with respect to P1′ position was determined using ZAX (benzyloxycarbonyl-Ala-Xaa) substrates. The TcMCP activities were assayed using the ninhydrin method [17] with 1 mM ZAX as substrate at 30 °C in their optimal buffers. One unit of enzyme was defined as the amount of enzyme that produced a ninhydrin-positive substance corresponding to 1 μmol of amino acid per min.

pH profile and thermostability

The pH profiles of the TcMCPs were determined by incubating the enzymes for 5 min at 25 °C before the addition of the substrate in the following buffers at 100 mM: Mes (pH 5–6.7), Mops (pH 6.5–7.9) and Hepes (pH 7–8.2). For TcMCP-2, 50 mM Tris/HCl, pH 7.6–9, was used in addition.

Thermostability was analysed by measuring residual TcMCP activities after pre-incubating both enzymes for 5 min at a given temperature in their optimal buffers.

Effects of metal ions

Metal-ion-dependence was investigated by assaying TcMCP activities after pre-incubation of bacterial crude extracts (5 μl, 5 min) with the metal chlorides. Purified TcMCPs (≈200 ng) were also tested to confirm the effects seen in crude extracts. TcMCP-1 residual activity was assayed using 200 μM FA-Ala-Lys in 100 mM Mes, pH 6.2, whereas TcMCP-2 activity was analysed with 100 μM FA-Phe-Phe in 50 mM Tris/HCl, pH 7.6.

Metal cations were also tested for their ability to reactivate metal-depleted TcMCPs (apo-TcMCPs). The recombinant TcMCP–GST fusion proteins were dialysed against 10 mM EDTA in 50 mM Tris/HCl, pH 7.6, for 16 h at 4 °C. EDTA was removed using a PD-10 column. Apo TcMCPs were incubated for 5 min with metal chlorides (0.01–10 mM) before activity was assayed.

Preparation of parasite extracts

T. cruzi CL Brener clone cells (1×109) were broken by three cycles of freezing at −20 °C and thawing. The parasite pellets were extracted with 200 μl of 50 mM Tris/HCl, pH 7.6, containing 1 mM PMSF and 10 μM E-64 [trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane]. The preparation was centrifuged at 26900 g for 30 min at 4 °C). The pellet was extracted again with the same buffer and centrifuged under identical conditions. The combined supernatants were centrifuged at 26900 g for 30 min at 4 °C. The cell-free extract was retained and the pellet was discarded. Activity against FA-Ala-Lys substrate (200 μM) was assayed in 100 mM Mes, pH 6.2. The hydrolysis of FA-Phe-Phe (100 μM) was measured in 50 mM Tris/HCl, pH 7.6, containing 1 mM CoCl2.


Polyclonal antibodies against TcMCP-1 were obtained in rabbits using purified recombinant His-tagged TcMCP-1 as immunogen. Additional antisera were also raised in rabbits by using the synthetic peptide DLMDGNIEAEEVPRC, corresponding to amino acid residues 371–384 of TcMCP-1 and the synthetic peptide GLIEGKLRVEDVPAC, corresponding to the equivalent amino acid residues in TcMCP-2. The C-terminal cysteine residue was added in both cases for the covalent linking of the peptides to the carrier KLH (keyhole-limpet haemocyanin) (Pierce).

Western blot analysis

For Western blots, soluble T. cruzi extracts (100 μg) were resolved on a SDS/10% polyacrylamide gel, transferred on to a nitrocellulose Hybond™ ECL® (enhanced chemiluminescence) membrane (Amersham Biosciences), blocked in 3% (w/v) non-fat dried milk powder, 2% glycine and 150 mM NaCl in 50 mM Tris/HCl, pH 7.6 [TBS (Tris-buffered saline)] and incubated with TcMCP-1 antiserum (1:1000, 2 h) or anti-TcMCP-2 peptide (1:500, 2 h) in blocking buffer. Blots were washed twice with TBS for 10 min, once with 0.05% Nonidet P-40 in TBS for 10 min and twice with TBS for 10 min. Horseradish-peroxidase-conjugated goat anti-rabbit IgG (Sigma) (1:10000, 1 h) in blocking buffer was used as secondary antibody. The membranes were washed again and developed using SuperSignal WestPico Chemiluminescent Substrate (Pierce).

Immunofluorescence experiments

For immunofluorescence experiments, parasites from different life cycle stages of the T. cruzi CL Brener clone were air-dried on poly(L-lysine)-coated glass coverslips, fixed with 4% (w/v) paraformaldehyde in PBS (20 min), incubated with 25 mM NH4Cl (10 min), permeabilized with 2% BSA, 0.1% saponin, 2% normal goat serum in PBS (30 min) and incubated with anti-TcMCP-1 rabbit serum (1:500) or anti-TcMCP-2 peptide rabbit serum (1:500) with 2% BSA, 0.1% saponin in PBS (1 h). Cover-slips were washed three times with PBS for 1 min. Alexa Fluor® 488-conjugated goat anti-rabbit IgG (H+L) (Molecular Probes) (1:1000) (1 h) was used as secondary antibody. Nucleus and kinetoplast were stained with DAPI (4′,6-diamidino-2-phenylindole) (5 mg·ml−1). Coverslips were washed again three times with PBS for 1 min and mounted using 15 μl of Fluor Save (Calbiochem). Samples were examined with a Nikon Eclipse E6000 microscope using appropriate fluorescence filters and photographed with a digital Spot RT Slider camera.


The T. cruzi genome encodes two MCPs of the M32 family

Following previous work in which we characterized a serine carboxypeptidase [11], we obtained a partial genomic clone containing the sequence of what seemed like another (but different) carboxypeptidase. Screening of the then available T. cruzi genome data (unassembled genomic sequences) using this sequence as a query led us to assemble two DNA contigs encoding putative proteins with sequence similarity to thermostable carboxypeptidases of the M32 family. To avoid dealing with possible assembly artefacts we proceeded to (i) amplify, clone and sequence the genes, and (ii) check the accuracy of the assembly by Southern blot with selected restriction enzymes. Using specific primers (see the Materials and methods section), we amplified and sequenced both genes which we named TcMCP-1 and TcMCP-2 and deposited in the DDBJ, EMBL, GenBank® and GSDB Nucleotide Sequence Databases under accession numbers AJ704363 and AJ704364. The TcMCP genes contained an ORF of 1512 bp and encoded polypeptides with predicted molecular masses of 57.7 kDa and 58.3 kDa. Not surprisingly, we found that our versions of these genes (also from T. cruzi CL Brener) have minor point differences when compared with those from the T. cruzi Genome Project (accession numbers Tc00.1047053504153.160 and Tc00.1047053504045.60). These differences are probably due to the merging of the two alleles into a single consensus sequence during genome assembly, since for all differing sites we were able to find support from individual (i.e. unassembled) GSS (Genome Sequence Survey) sequences.

In order to confirm the estimated copy number of TcMCP genes and check the accuracy of our assembly we performed Southern blot analysis. T. cruzi genomic DNA digested with restriction enzymes that do not cut within the TcMCP-1 or TcMCP-2 ORF (BamHI, BstXI, EcoRV, NcoI, NdeI and XhoI) yielded single bands when probed with the corresponding full-length TcMCP-1 or TcMCP-2 gene, whereas endonucleases with a single restriction site inside the ORFs (AvaI, PstI, AccI and SacII) rendered two bands (Figure 1). Some enzymes (HincII and KpnI) produced three bands when probed with the TcMCP-2 gene which correspond to the two TcMCP-2 alleles. Thus TcMCP genes are present as a single copy per haploid genome.

Figure 1
Determination of TcMCP copy number

Sequence and comparative genomics analysis

Both TcMCP proteins were subjected to domain analysis against Interpro [23] and Smart [24] databases which confirmed the presence in both T. cruzi enzymes of amino acid motifs related to M32 peptidases. Figure 2(A) shows the amino acid alignment of TcMCP-1, TcMCP-2 and five prokaryotic members of the M32 family. The TcMCPs described here shared 64% identity with each other and displayed the highest sequence identity (46–36%) with those M32 proteins of the proteobacteria group. The sequence of TcMCPs contains the canonical HEXXH motif that includes the active-site glutamic acid residue at position 268 [18], flanked by two histidine residues (positions 267 and 271) that co-ordinate the catalytic metal ion (Figure 2A). TcMCPs also present the third metal ligand glutamic acid residue (position 296) of the HEGQ signature conserved in all M32 peptidases. Additional key residues, proposed to bind the C-terminal carboxylate group and promote release of the cleaved amino acid product, are conserved when comparing TcMCPs with the crystallized PfuCP, these residues include Arg348 and Asp407 from the IRXXAD and GXXQDXHW motifs respectively.

Figure 2
Multiple sequence alignments of MCPs belonging to the M32 family

An extensive search of the publicly available genome sequences at the NCBI non-redundant (nr) database (http://www.ncbi.nlm.nih.gov) using the BLAST (basic local alignment search tool) allowed us to identify M32 MCP genes in multiple prokaryotic organisms. However, their phylogenetic distribution was quite peculiar, as trypanosomes and leishmanias were the only eukaryotic organisms in which members of this family were found (see Supplementary Table S1 at http://www.BiochemJ.org/bj/401/bj4010399add.htm). To analyse further the phylogenetic relationships of protozoan parasite MCPs, an unrooted tree using the full-length amino acid sequences of several M32 peptidases was constructed. As shown in Figure 2(B), MCPs from trypanosomatids seem to be closely related to the enzymes of the proteobacteria group.

Expression and purification of recombinant TcMCPs

On the basis of these particular findings, we decided to analyse the enzymatic properties of both T. cruzi enzymes. The full-length TcMCP genes were cloned into the bacterial expression vector pTrcHisA, and expressed in E. coli XL1 Blue cells as N-terminally polyHis-tagged recombinant enzymes. TcMCP-2 was purified in one step using Co-NTA affinity chromatography with a yield of 1–2.5 mg/l of bacterial culture. As recombinant TcMCP-1 was inhibited by Co2+, it had to be purified using a conventional purification scheme including three steps, namely gel filtration and two ion-exchange chromatography steps. In a standard preparation, 0.33 mg of homogeneous TcMCP-1 was obtained from 21 mg of protein in the bacterial cell-free extract, with a 20.4-fold purification and 32% recovery (Table 1). Recombinant TcMCPs were evaluated for purity on Coomassie Blue- or silver-stained SDS/10% polyacrylamide gels. The apparent subunit molecular masses of both purified enzymes (approx. 58 kDa) were in good agreement with the calculated masses of the affinity-tagged products of the corresponding genes (approx. 62 kDa) (Figure 3). TcMCP-1 and TcMCP-2 eluted in a single peak from a Superose 12HR 10/30 column with an apparent molecular mass corresponding to 128 kDa and 132 kDa respectively, indicating that both enzymes associate into catalytically active homodimers.

Figure 3
Expression and purification of recombinant TcMCPs from E. coli
Table 1
Purification of recombinant TcMCP-1

Purified recombinant TcMCP proteins were used in enzymatic assays with N-blocked furylacryloyl dipeptides commonly employed for screening carboxypeptidases. These experiments revealed that recombinant TcMCP-2 exhibits a significant hydrolytic activity against the carboxypeptidase A (subfamily M14A) substrate FA-Phe-Phe at pH 7.6–8, whereas recombinant TcMCP-1 optimally cleaved the CPB (carboxypeptidase B) (subfamily M14B) substrate FA-Ala-Lys at pH 6.2–7.3. In both cases, carboxypeptidase activities declined under mildly acidic conditions (pH 5.5). Metal-ion chelators EDTA (10 mM) and o-phenanthroline (1 mM) were strong inhibitors of both proteins, consistent with the TcMCPs being metal-dependent enzymes. As expected, the serine peptidase inhibitor PMSF (2 mM) and the cysteine peptidase inhibitor E-64 (10 μM) had no effect on TcMCPs activities (results not shown).

Effects of metal ions

Table 2 shows the effects of different metal ions on purified TcMCPs. Recombinant TcMCP-1 activity on FA-Ala-Lys was inhibited by metal ions such as Co2+, Mn2+ and Ni2+. Ca2+ and Mg2+ were also slightly inhibitory at higher concentrations. The pronounced inhibition by Ni2+ and Co2+ probably accounts for the poor specific activities that we obtained when recombinant TcMCP-1 was purified on Ni- or Co-NTA resin. In contrast, recombinant TcMCP-2 activity on FA-Phe-Phe was stimulated by Co2+, whereas Mn2+ and Ni2+ had little effect. Zn2+, the most common metallopeptidase cofactor, inhibited both recombinant TcMCPs at micromolar excess. A similar phenomenon was reported for several zinc peptidases [2527] and was attributed to a second Zn2+ ion that binds the active site [28,29].

Table 2
Effect of bivalent cations on recombinant TcMCP activities

To study the effects of bivalent cations on metal-depleted TcMCPs (apo-TcMCPs), the GST-fused recombinant enzymes were dialysed against the metal-ion chelator EDTA (10 mM) as described in the Materials and methods section, leading to the inactive apo-enzymes. Incubation with 0.1 mM Mn2+ or Co2+ reactivated apo-TcMCP-1 by up to 28% and 20–24% respectively. Zn2+ had less effect (5–6% maximal reactivation at 10 μM). Higher metal concentrations did not afford a higher recovery of activity and resulted in enzyme inhibition. Co2+ at 1 mM completely restored apo-TcMCP-2 activity on FA-Phe-Phe, whereas 1 mM MnCl2 reactivated the enzyme up to 82–90%. Zn2+ had no effect on apo-TcMCP-2. This behaviour was also reported for PfuCP, which was activated in the presence of Co2+, but not in the presence of Zn2+ [17]. The poor activity recovery by apo-TcMCP-1 might be due to its lower stability, since TcMCP-1 control (dialysed against 50 mM Tris/HCl, pH 7.6) lost almost 50% of its activity compared with the TcMCP-2 control. It has been suggested for several metalloproteins that removal of the bivalent cation induces conformational changes that result in enzyme inactivation [30,31].

Kinetic parameters and P1′ preference

Kinetic parameters of recombinant TcMCP-1 activity in 100 mM Mes, pH 6.2, with FA-Ala-Lys as substrate were determined from a Lineweaver–Burk plot: Km 166 μM, kcat 20 s−1. When Co2+ was added to the reaction mixture, FA-Ala-Lys was hydrolysed at a lower rate, with a kcat value 28% of that seen in its absence. Interestingly, recombinant TcMCP-1 activity on FA-Phe-Phe was enhanced in the presence of Co2+, although the substrate was much less efficiently hydrolysed: kcat/Km 9.6 s−1·mM−1. In the absence of Co2+, it was possible to detect activity on FA-Phe-Phe only when 10-fold more enzyme was used (up to 5 μg). Recombinant TcMCP-2 purified by IMAC (immobilized metal-ion-affinity chromatography) Co2+ had a Km value of 24 μM for the hydrolysis of FA-Phe-Phe in 50 mM Tris/HCl, pH 7.6 (Table 3).

Table 3
Kinetic constants for the hydrolysis of synthetic substrates by recombinant TcMCPs

To characterize further the substrate preference with respect to the P1′ position of the identified TcMCPs, several commercially available ZAX (X represents a different amino acid as indicated by the single-letter amino acid code) dipeptides were used. As shown in Figure 4, the recombinant TcMCP-1 acted best on substrates having a basic amino acid at P1′ position. Activity was very low with hydrophobic C-terminal residues. In contrast, recombinant TcMCP-2 seems to have preference for aliphatic, even glycine, and aromatic amino acids, not acting on basic substrates (ZAR or ZAK). For both enzymes, no activity was seen against ZAH, ZAP, ZAD or ZAE.

Figure 4
P1′ preference of recombinant TcMCPs

We have also performed similar experiments with the full-length TcMCP-1 and TcMCP-2 produced as GST-fusion proteins. These experiments confirmed the above results for substrate specificity and sensitivity to metal cations obtained by using His-tagged TcMCPs (results not shown).

TcMCPs are not thermostable

As both M32 carboxypeptidases characterized previously were thermostable, many M32 sequences belonging to mesophilic organisms were subsequently annotated as putative thermostable carboxypeptidases, including the TcMCP-2 gene. To confirm or discard this possibility, we incubated recombinant TcMCPs at different temperatures. Both enzymes drastically decreased their activity in response to increasing temperatures. Residual activities measured under standard conditions after 5 min of incubation at 50 °C were 21.4% and 27.5% for TcMCP-1 and TcMCP-2 respectively, as expected from a mesophilic organism.

Expression of TcMCPs in T. cruzi

In order to analyse the expression of TcMCPs in all developmental stages of T. cruzi, we obtained antibodies against TcMCP-1 and TcMCP-2 (see the Materials and methods section). Cell-free extracts of epimastigotes, amastigotes, cell-derived trypomastigotes and metacylic trypomastigotes were subjected to Western blot analysis. Antibodies raised against the recombinant TcMCP-1 recognized a single band with an apparent molecular mass of 59 kDa in all life cycle stages of the parasite (Figure 5A). On the other hand, polyclonal anti-TcMCP-2 peptide serum solely detected a 58 kDa band in soluble extracts prepared from the epimastigote and metacyclic forms (Figure 5B). In good agreement with the results presented above, carboxypeptidase activity against FA-Ala-Lys was detected in all developmental stages of T. cruzi, whereas the FA-Phe-Phe substrate was hydrolysed solely by the parasite insect stages (Figure 5C). These data suggest a differential pattern of expression of TcMCP-2 during the T. cruzi life cycle.

Figure 5
Differential expression of MCPs in T. cruzi life cycle stages

TcMCP subcellular localization

The subcellular localization of TcMCPs was studied by indirect immunofluorescence as described in the Materials and methods section. T. cruzi cells were fixed and permeabilized with saponin before antibody binding. Polyclonal antiserum raised against recombinant TcMCP-1 or TcMCP-2 peptide yielded a diffuse uniform fluorescence throughout the cytosol of the epimastigote and metacyclic forms of the parasite (Figure 6). Mammalian stages solely revealed reactive material distributed throughout the cell bodies of the parasites when they were incubated with TcMCP-1 antiserum. On the other hand, amastigotes probed with anti-(TcMCP-2 peptide) antibody presented low labelling, whereas no signal could be detected in cell-derived trypomastigotes. These observations, together with those derived from analysis of the primary sequences (i.e. absence of a predicted signal peptide) suggest that both TcMCPs are cytosolic enzymes.

Figure 6
TcMCP subcellular localization


In the present paper, we report the cloning, genetic analysis and biochemical characterization of two novel MCPs of the M32 family from T. cruzi CL Brener clone. In contrast with cruzipain [32] and TcCBP [11], TcMCP genes are present in a single copy per haploid genome. Their encoded proteins displayed 20–60% identity with other M32 peptidases, showing the higher similarity scores with those of the proteobacteria group. The TcMCPs described here lack the canonical HEXXE(X)123−132H motif characteristic of the M14 family of carboxypeptidases (subfamilies M14A, M14B and M14C) and instead contain the HEXXH signature present in metalloendopeptidases, such as thermolysin (family M4) [18]. This work represents the first identification of a M32 peptidase from any eukaryotic organism.

To explore further the functional relevance of TcMCP proteins, we performed enzymatic analysis with both recombinant enzymes (TcMCP-1 and -2) produced in E. coli. This analysis provided evidence that these eukaryotic proteins are catalytically active carboxypeptidases that exhibit sensitivity to general metallopeptidase inhibitors. Despite their identity (64%), the TcMCPs showed marked differences. Whereas TcMCP-2 could cleave aliphatic, neutral and aromatic residues at the P1′ position, TcMCP-1 exhibited a narrow substrate specificity, acting best on basic residues at a lower pH, resembling the subfamily M14B. This makes TcMCP-1 different from those enzymes of the M32 family characterized to date: TaqCP and PfuCP, which exhibited broad substrate specificity for most peptides, except for those containing C-terminal acidic residues [14,17]. Intriguingly, TcMCP-1 substrate specificity could also be modulated by metal cations. Thus the presence of Co2+ ions enhanced the activity on FA-Phe-Phe, whereas it inhibited the activity on FA-Ala-Lys. A change in substrate specificity, related to a change in the metal cofactor, has been reported for CPB from human plasma: with cobalt at the active site, CPB activity towards the ester substrate hippuryl-L-arginic acid was stimulated, whereas hydrolysis of the peptide substrate hippuryl-L-arginine was inhibited. The opposite trend was observed with cadmium at the active site [33]. Unfortunately, there are no data on the cytoplasmic levels of Co2+, Mn2+ and Ni2+ in T. cruzi, therefore we cannot speculate on the possibility that this substrate modulation is operating in vivo.

In solution, the recombinant TcMCP-1 and TcMCP-2 exist as homodimers of 128 kDa and 132 kDa respectively, as determined by gel-filtration chromatography. In good agreement with these results, the primary structure of TcMCPs show conserved hydrophobic amino acid residues (Ala24, Pro33, Gly36, Ala42, Ala43 and Leu47) and residues involved in the formation of salt bridges (Lys13, Asp53 and Asp28, Arg246) that were supposed to be involved in PfuCP dimer stabilization, some of which are lost in the monomeric TaqCP [18]. There is no evidence of post-translational processing, since the native TcMCPs were detected by Western blot analysis at a molecular mass corresponding to the size deduced from the sequence data. A different pattern of expression of both TcMCPs was detected during the T. cruzi life cycle. Whereas TcMCP-1 is expressed at similar levels throughout the life cycle of the parasite, TcMCP-2 is found mainly in the insect vector stages, suggesting that its expression is developmentally regulated.

Orthologue genes of TcMCP-1 (displaying 59–72% identity with the corresponding T. cruzi enzyme) have been annotated in the genomes of T. brucei and L. major (see Supplementary Table S1). Interestingly, all of these genes share the same genomic context (i.e. they are present in syntenic regions). In contrast, analysis of the TcMCP-2 genomic locus suggest that this gene is species-specific, since it occurs at a non-syntenic chromosome region. Nevertheless, a phylogenetic analysis of parasite MCPs clustered TcMCP-2 within TcMCP-1-related proteins, suggesting that it could have arisen by gene duplication (see Supplementary Figure S1 at http://www.BiochemJ.org/bj/401/bj4010399add.htm). Likewise, multiple M32 genes and pseudogenes were identified through searches against the L. major genome [34] and other Leishmania spp. genomes whose sequencing is underway [35]. These findings illustrate the complexity of the M32 family within the trypanosomatids which is not seen in prokaryotic organisms and might be the result of specific adaptations to distinct species-specific selection pressures and survival strategies of each organism.

An additional distinctive feature of the M32 family is its particular phylogenetic distribution. In fact, our in silico analysis revealed that these enzymes are widely distributed in bacterial and archaeal organisms, but are absent in most eukaryotic genomes fully sequenced so far. This phylogenetic distribution could be explained by considering different evolutionary scenarios. One possibility is that of horizontal gene transfer between an ancestral proteobacterium (the most likely donor based on the phylogenetic tree in Figure 2B) and an ancestral trypanosomatid. This hypothetical scenario explains the presence of M32 genes in trypanosomatids and their absence in other eukaryotic organisms. A similar suggestion has been made for the three last enzymes of haem biosynthesis (coproporphyrinogen III oxidase, protoporphyrinogen IX oxidase and ferrochelatase) of L. major and the third enzyme of the aminoethylphosphonate pathway (aminoethylphosphonate transaminase), found in L. major and T. cruzi [34]. In another possible scenario, the M32 genes were lost in an ancestral eukaryote, sometime after the ancestor of present-day trypanosomatids had branched off the tree. This hypothesis can also explain the absence of M32 genes in eukaryotic organisms that evolved from this hypothetical ancestor lacking M32 genes. However, to explain the apparent absence of M32 genes in early branching eukaryotes (such as Giardia lamblia, 11.3× genome coverage; Entamoeba histolytica, 8× genome coverage; or Trichomonas vaginalis, 6× genome assembly), one would have to postulate additional gene loss events. In the light of these observations, the first scenario stands as the most parsimonious. However, given that there is limited coverage of complete genome sequences from the early branches of the eukaryotic tree (mostly because of the paucity of extant organisms), the second evolutionary scenario (gene loss in other early branches) cannot be discarded.

No biological function has yet been assigned to peptidases of the M32 family. Nevertheless, microarray experiments on the hyperthermophilic archaeon P. furiosus suggest that M32 peptidases may be involved in the utilization of peptides and proteins for nutrition in this organism, since the relative transcript levels of the ORF PF0456 (coding for an M32 peptidase) are up-regulated 2.6-fold when cells are grown in media containing peptides as the primary carbon source compared with those grown in maltose [36]. Additional experiments performed on Bacillus subtilis knockout for the YpwA gene have shown that the enzyme is not essential for growth in glucose medium. Notably, this mutant showed improved growth in terms of rate and yield of biomass formation [37]. Additional clues about the possible roles of these enzymes can be derived from the analysis of the crystal structure of PfuCP. This analysis revealed that the enzyme has a fold similar to those of ACE (angiotensin-converting enzyme) [38,39], ACE2 [40], neurolysin [18] and TOP (thimet oligopeptidase) [41], all of which are zinc metallopeptidases with no detectable sequence similarity to M32 peptidases. Whereas ACE is a crucial regulator of the renin–angiotensin system, converting the inactive decapeptide angiotensin I into the potent vasoconstrictor angiotensin II, many biologically active peptides could be hydrolysed by ACE2 [42]. TOP has been implicated in the metabolism of a number of small peptides in the central nervous system, and recent studies have also demonstrated that this enzyme is primarily responsible for degrading peptides released from proteasomes [43], thereby limiting the extent of antigen presentation by MHC class I molecules [44]. Thus we can speculate that a major role of the TcMCPs might be the degradation of peptides, such as those produced by the proteasomes, in the cytosol. However, a possible role in the processing of proteins and small regulatory peptides cannot be excluded at present.

Previous studies on M32 peptidases focused their attention on the possibility of using these enzymes in C-terminal ladder sequencing of proteins and peptides. Today, apart from the possible biotechnological applications, it is clear that M32 sequences are present in human pathogens such as Vibrio, Rickettsia, Yersinia, Legionella, Leptospira, Listeria, Enterococcus, Bacillus and also the Trypanosomatidae family. Thus the apparent absence of these enzymes in most eukaryotic organisms, including mammals, makes the M32 family a unique group of peptidases, particularly suitable for exploration as possible drug targets against these organisms. Validation of TcMCP-1 and TcMCP-2 as targets will require further studies with deletion mutants and permeant inhibitors.

Online data

Supplementary Figure S1:
Supplementary Table S1. M32 peptidases within trypanosomatids:


This work was performed with a grant from ANPCyT (Agencia Nacional de Promoción Científica y Tecnológica), SECYT (Secretaria de Ciencia y Tecnica) (Argentina), PICT 01-15042. J. J. C. and F. A. are members of the research career, and G. N. is a research fellow of the Argentinean National Research Council [CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas)]. F. P. was a research fellow of the Universidad Nacional de General San Martín. We are indebted to Ms Ulla Engström and Dr Ulf Hellman from the Ludwig Institute for Cancer Research, Uppsala Branch, Sweden, for the synthesis of the peptides used to produce antibodies.


1. Barrett M. P., Burchmore R. J., Stich A., Lazzari J. O., Frasch A. C., Cazzulo J. J., Krishna S. The trypanosomiases. Lancet. 2003;362:1469–1480. [PubMed]
2. Klemba M., Goldberg D. E. Biological roles of proteases in parasitic protozoa. Annu. Rev. Biochem. 2002;71:275–305. [PubMed]
3. Cazzulo J. J. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr. Top. Med. Chem. 2002;2:1261–1271. [PubMed]
4. Garcia M. P., Nobrega O. T., Teixeira A. R., Sousa M. V., Santana J. M. Characterisation of a Trypanosoma cruzi acidic 30 kDa cysteine protease. Mol. Biochem. Parasitol. 1998;91:263–272. [PubMed]
5. Burleigh B. A., Caler E. V., Webster P., Andrews N. W. A cytosolic serine endopeptidase from Trypanosoma cruzi is required for the generation of Ca2+ signaling in mammalian cells. J. Cell Biol. 1997;136:609–620. [PMC free article] [PubMed]
6. Bastos I. M., Grellier P., Martins N. F., Cadavid-Restrepo G., de Souza-Ault M. R., Augustyns K., Teixeira A. R., Schrevel J., Maigret B., da Silveira J. F., Santana J. M. Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. Biochem. J. 2005;388:29–38. [PMC free article] [PubMed]
7. Cuevas I. C., Cazzulo J. J., Sanchez D. O. gp63 homologues in Trypanosoma cruzi: surface antigens with metalloprotease activity and a possible role in host cell infection. Infect. Immun. 2003;71:5739–5749. [PMC free article] [PubMed]
8. de Diego J. L., Katz J. M., Marshall P., Gutierrez B., Manning J. E., Nussenzweig V., Gonzalez J. The ubiquitin–proteasome pathway plays an essential role in proteolysis during Trypanosoma cruzi remodeling. Biochemistry. 2001;40:1053–1062. [PubMed]
9. Gonzalez J., Ramalho-Pinto F. J., Frevert U., Ghiso J., Tomlinson S., Scharfstein J., Corey E. J., Nussenzweig V. Proteasome activity is required for the stage-specific transformation of a protozoan parasite. J. Exp. Med. 1996;184:1909–1918. [PMC free article] [PubMed]
10. Healy N., Greig S., Enahoro H., Roberts H., Drake L., Shaw E., Ashall F. Detection of peptidases in Trypanosoma cruzi epimastigotes using chromogenic and fluorogenic substrates. Parasitology. 1992;104:315–322. [PubMed]
11. Parussini F., Garcia M., Mucci J., Aguero F., Sanchez D., Hellman U., Aslund L., Cazzulo J. J. Characterization of a lysosomal serine carboxypeptidase from Trypanosoma cruzi. Mol. Biochem. Parasitol. 2003;131:11–23. [PubMed]
12. Vendrell J., Querol E., Aviles F. X. Metallocarboxypeptidases and their protein inhibitors: structure, function and biomedical properties. Biochim. Biophys. Acta. 2000;1477:284–298. [PubMed]
13. Vendrell J., Aviles F. X. Carboxypeptidases. In: Turk V., editor. Proteases: New Perspectives. Basel: Birkhäuser Verlag; 1999. pp. 13–34.
14. Lee S. H., Minagawa E., Taguchi H., Matsuzawa H., Ohta T., Kaminogawa S., Yamauchi K. Purification and characterization of a thermostable carboxypeptidase (carboxypeptidase Taq) from Thermus aquaticus YT-1. Biosci. Biotechnol. Biochem. 1992;56:1839–1844. [PubMed]
15. Lee S. H., Taguchi H., Yoshimura E., Minagawa E., Kaminogawa S., Ohta T., Matsuzawa H. The active site of carboxypeptidase Taq possesses the active-site motif His-Glu-X-X-His of zinc-dependent endopeptidases and aminopeptidases. Protein Eng. 1996;9:467–469. [PubMed]
16. Rawlings N. D., Morton F. R., Barrett A. J. MEROPS: the peptidase database. Nucleic Acids Res. 2006;34:D270–D272. [PMC free article] [PubMed]
17. Cheng T. C., Ramakrishnan V., Chan S. I. Purification and characterization of a cobalt-activated carboxypeptidase from the hyperthermophilic archaeon Pyrococcus furiosus. Protein Sci. 1999;8:2474–2486. [PMC free article] [PubMed]
18. Arndt J. W., Hao B., Ramakrishnan V., Cheng T., Chan S. I., Chan M. K. Crystal structure of a novel carboxypeptidase from the hyperthermophilic archaeon Pyrococcus furiosus. Structure. 2002;10:215–224. [PubMed]
19. Zingales B., Pereira M. E., Almeida K. A., Umezawa E. S., Nehme N. S., Oliveira R. P., Macedo A., Souto R. P. Biological parameters and molecular markers of clone CL Brener the reference organism of the Trypanosoma cruzi genome project. Mem. Inst. Oswaldo Cruz. 1997;92:811–814. [PubMed]
20. Franke de Cazzulo B. M., Martinez J., North M. J., Coombs G. H., Cazzulo J. J. Effects of proteinase inhibitors on the growth and differentiation of Trypanosoma cruzi. FEMS Microbiol. Lett. 1994;124:81–86. [PubMed]
21. Maniatis T., Fritsch E. F., Sambrook J. Molecular Cloning: a Laboratory Manual. 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989.
22. Southern E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 1975;98:503–517. [PubMed]
23. Quevillon E., Silventoinen V., Pillai S., Harte N., Mulder N., Apweiler R., Lopez R. InterProScan: protein domains identifier. Nucleic Acids Res. 2005;33:W116–W120. [PMC free article] [PubMed]
24. Letunic I., Copley R. R., Pils B., Pinkert S., Schultz J., Bork P. SMART 5: domains in the context of genomes and networks. Nucleic Acids Res. 2006;34:D257–D260. [PMC free article] [PubMed]
25. Mallya S. K., Van Wart H. E. Mechanism of inhibition of human neutrophil collagenase by gold(I) chrysotherapeutic compounds: interaction at a heavy metal binding site. J. Biol. Chem. 1989;264:1594–1601. [PubMed]
26. Larsen K. S., Auld D. S. Carboxypeptidase A: mechanism of zinc inhibition. Biochemistry. 1989;28:9620–9625. [PubMed]
27. Kerr M. A., Kenny A. J. The molecular weight and properties of a neutral metallo-endopeptidase from rabbit kidney brush border. Biochem. J. 1974;137:489–495. [PMC free article] [PubMed]
28. Gomez-Ortiz M., Gomis-Ruth F. X., Huber R., Aviles F. X. Inhibition of carboxypeptidase A by excess zinc: analysis of the structural determinants by X-ray crystallography. FEBS Lett. 1997;400:336–340. [PubMed]
29. Holland D. R., Hausrath A. C., Juers D., Matthews B. W. Structural analysis of zinc substitutions in the active site of thermolysin. Protein Sci. 1995;4:1955–1965. [PMC free article] [PubMed]
30. Kayestha R., Sumati, Hajela K. Studies on metal induced conformation changes in a peripheral blood lymphocyte lectin. Biochim. Biophys. Acta. 1996;1289:51–56. [PubMed]
31. Kerovuo J., Lappalainen I., Reinikainen T. The metal dependence of Bacillus subtilis phytase. Biochem. Biophys. Res. Commun. 2000;268:365–369. [PubMed]
32. Campetella O., Henriksson J., Aslund L., Frasch A. C., Pettersson U., Cazzulo J. J. The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is encoded by multiple polymorphic tandemly organized genes located on different chromosomes. Mol. Biochem. Parasitol. 1992;50:225–234. [PubMed]
33. Tan A. K., Eaton D. L. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 1995;34:5811–5816. [PubMed]
34. Ivens A. C., Peacock C. S., Worthey E. A., Murphy L., Aggarwal G., Berriman M., Sisk E., Rajandream M. A., Adlem E., Aert R., et al. The genome of the kinetoplastid parasite, Leishmania major. Science. 2005;309:436–442. [PMC free article] [PubMed]
35. Hertz-Fowler C., Peacock C. S., Wood V., Aslett M., Kerhornou A., Mooney P., Tivey A., Berriman M., Hall N., Rutherford K., et al. GeneDB: a resource for prokaryotic and eukaryotic organisms. Nucleic Acids Res. 2004;32:D339–D343. [PMC free article] [PubMed]
36. Schut G. J., Brehm S. D., Datta S., Adams M. W. Whole-genome DNA microarray analysis of a hyperthermophile and an archaeon: Pyrococcus furiosus grown on carbohydrates or peptides. J. Bacteriol. 2003;185:3935–3947. [PMC free article] [PubMed]
37. Fischer E., Sauer U. Large-scale in vivo flux analysis shows rigidity and suboptimal performance of Bacillus subtilis metabolism. Nat. Genet. 2005;37:636–640. [PubMed]
38. Natesh R., Schwager S. L., Sturrock E. D., Acharya K. R. Crystal structure of the human angiotensin-converting enzyme–lisinopril complex. Nature. 2003;421:551–554. [PubMed]
39. Brew K. Structure of human ACE gives new insights into inhibitor binding and design. Trends Pharmacol. Sci. 2003;24:391–394. [PubMed]
40. Towler P., Staker B., Prasad S. G., Menon S., Tang J., Parsons T., Ryan D., Fisher M., Williams D., Dales N. A., et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 2004;279:17996–18007. [PubMed]
41. Ray K., Hines C. S., Coll-Rodriguez J., Rodgers D. W. Crystal structure of human thimet oligopeptidase provides insight into substrate recognition, regulation, and localization. J. Biol. Chem. 2004;279:20480–20489. [PubMed]
42. Guy J. L., Lambert D. W., Warner F. J., Hooper N. M., Turner A. J. Membrane-associated zinc peptidase families: comparing ACE and ACE2. Biochim. Biophys. Acta. 2005;1751:2–8. [PubMed]
43. Saric T., Graef C. I., Goldberg A. L. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J. Biol. Chem. 2004;279:46723–46732. [PubMed]
44. Kim S. I., Pabon A., Swanson T. A., Glucksman M. J. Regulation of cell-surface major histocompatibility complex class I expression by the endopeptidase EC (thimet oligopeptidase) Biochem. J. 2003;375:111–120. [PMC free article] [PubMed]
45. Thompson J. D., Higgins D. G., Gibson T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting positions-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–4680. [PMC free article] [PubMed]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Conserved Domains
    Conserved Domains
    Link to related CDD entry
  • MedGen
    Related information in MedGen
  • Nucleotide
    Published Nucleotide sequences
  • Pathways + GO
    Pathways + GO
    Pathways, annotations and biological systems (BioSystems) that cite the current article.
  • Protein
    Published protein sequences
  • PubMed
    PubMed citations for these articles
  • Taxonomy
    Related taxonomy entry
  • Taxonomy Tree
    Taxonomy Tree

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...